| 18FDG-PET/CT: a useful tool for the management of patients in infectious diseases M Pichon, N Mikail, K Ben Ali, F Rouzet, C Burdet, Y Yazdanpanah, V Joly, ... Infectious Diseases 49 (2), 155-157, 2017 | 1 | 2017 |
| A clinical study provides the first direct evidence that interindividual variations in fecal β-lactamase activity affect the gut mycobiota dynamics in response to β-lactam … M Delavy, C Burdet, N Sertour, S Devente, JD Docquier, N Grall, S Volant, ... MBio 13 (6), e02880-22, 2022 | 9 | 2022 |
| A high prevalence of hereditary alpha-tryptasemia in pediatric mastocytoma M Madrange, J Rossignol, C Devin, L Bekel, N Bellon, A Welfringer-Morin, ... Allergy, 2024 | | 2024 |
| A Phase 3 Randomized Controlled Trial (MICROCARE) to Evaluate the Efficacy of DAV132 in Preventing Clostridioides Difficile Infection in Patients with Newly Diagnosed Acute … M Vehreschild, CH van Werkhoven, L Biehl, A Dane, MEA de Kraker, ... Blood 138, 4437, 2021 | 1 | 2021 |
| Actualité de la rougeole M Caseris, C Burdet, R Lepeule, N Houhou, P Yeni, Y Yazdanpanah, ... Journal Européen des Urgences et de Réanimation 27 (3), 153-160, 2015 | 7 | 2015 |
| An elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes: Pathophysiological implications L Polivka, M Madrange, C Bulai-Livideanu, S Barete, T Ballul, A Neuraz, ... J. Allergy Clin. Immunol 10, 2023 | 1 | 2023 |
| An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 F Ader, N Peiffer-Smadja, J Poissy, M Bouscambert-Duchamp, D Belhadi, ... Clinical Microbiology and Infection 27 (12), 1826-1837, 2021 | 106 | 2021 |
| An update on measles M Caseris, C Burdet, R Lepeule, N Houhou, P Yeni, Y Yazdanpanah, ... La Revue de Médecine Interne 36 (5), 339-345, 2015 | 16 | 2015 |
| Antibiotic-induced dysbiosis predicts mortality in an animal model of Clostridium difficile infection C Burdet, S Sayah-Jeanne, TT Nguyen, P Hugon, F Sablier-Gallis, ... Antimicrobial agents and chemotherapy 62 (10), 10.1128/aac. 00925-18, 2018 | 21 | 2018 |
| Antiviral drugs in hospitalized patients with COVID-19-the DisCoVeRy trial A Florence, N PEIFFER-SMADJA, J POISSY, ... | | 2021 |
| Antiviral drugs in hospitalized patients with COVID-19-the DisCoVeRy trial F Ader, N Peiffer-Smadja, J Poissy, M Bouscambert-Duchamp, D Belhadi, ... MedRxiv, 2021.01. 08.20248149, 2021 | 11 | 2021 |
| APOBEC editing in HIV DNA proviral vif and pol long-reads issued from virologically suppressed patients included in the ANRS LAMIDOL trial. M Bertine, A Storto, V Joly, S Lameiras, C Burdet, S Baulande, ... Journal of the International AIDS Society 24 (S4), 25-26, 2021 | | 2021 |
| Association between SARS‐CoV‐2 viral kinetics and clinical score evolution in hospitalized patients N Néant, G Lingas, A Gaymard, D Belhadi, M Hites, T Staub, R Greil, ... CPT: Pharmacometrics & Systems Pharmacology 12 (12), 2027-2037, 2023 | 2 | 2023 |
| Association between the antibiotics use and recurrence in patients with resected non-metastatic colorectal cancer: EVADER-1, a nation-wide pharmaco-epidemiologic study. M Hilmi, I Khati, A Turpin, A Andremont, C Burdet, N Grall, J Vidal, ... medRxiv, 2023.09. 23.23296001, 2023 | | 2023 |
| Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 466 | 2021 |
| BMR-08 C Wemmert, A Leleu, FX Lescure, N Grall, J Belaid, C Burdet, M Lachatre, ... M decine et Maladies Infectieuses 4 (46), 26, 2016 | | 2016 |
| Caractéristiques des PVVIH d’origine maghrébine M Parisey, F Louni, E Bouvet, R Landman, Y Yazdanpanah, C Burdet Médecine et Maladies Infectieuses 47 (4), S141, 2017 | | 2017 |
| Caractéristiques des souches d’Escherichia coli résistantes aux quinolones dans le microbiote fécal après traitement par ciprofloxacine V de Lastours, A Bleibtreu, C Burdet, F Chau, E Denamur, B Fantin La Revue de medecine interne, A32, 2013 | | 2013 |
| Carbapenems and alternative beta-lactams for the treatment of infections due to ESBL-producing Enterobacteriaceae: what impact on intestinal colonization resistance? PL Woerther, R Lepeule, C Burdet, JW Decousser, E Ruppe, F Barbier Int J Antimicrob Agents 52, 762-770, 2018 | 2 | 2018 |
| Carbapenems and alternative β-lactams for the treatment of infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: what impact on intestinal colonisation … PL Woerther, R Lepeule, C Burdet, JW Decousser, É Ruppé, F Barbier International journal of antimicrobial agents 52 (6), 762-770, 2018 | 62 | 2018 |
